# EDGAR Filing Document

**Accession Number:** 0001817713
**File Stem:** 0001193125-26-187641
**Filing Date:** 2026-4
**Character Count:** 5430
**Document Hash:** f8173898cfd7e1c3e274348bb9208a92
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-187641.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001193125-26-187641

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260428

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Janux Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001817713
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822289112
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40475
- **FILM NUMBER:** 26909028

**BUSINESS ADDRESS:**
- **STREET 1:** 10955 VISTA SORRENTO PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 751-4493

**MAIL ADDRESS:**
- **STREET 1:** 10955 VISTA SORRENTO PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported):** April 28, 2026

------

Janux Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40475 | 82-2289112 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 10955 Vista Sorrento Parkway**,** Suite 200<br>San Diego**,** California |  | 92130 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 751-4493

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | JANX | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

In order to achieve a more equal balance of membership among the three classes of directors on the Board of Directors (the "Board") of Janux Therapeutics, Inc. (the "Company"), the Board determined that one of its members should be reclassified from Class III (with a term expiring at the Company's 2027 Annual Meeting of Stockholders) to Class II (with a term expiring at the Company's 2026 Annual Meeting of Stockholders).

Accordingly, on April 28, 2026, Eric Dobmeier agreed to resign from the Board and his position as a Class III director subject to, and contingent upon, his immediate reappointment as a Class II director. Effective immediately following Mr. Dobmeier's resignation, the Board reappointed him as a Class II director. The resignation and reappointment of Mr. Dobmeier was effected solely to rebalance the classes of directors on the Board and, for all other purposes, including the vesting and settlement of any outstanding equity awards and any other compensation to which Mr. Dobmeier is entitled to as a non-employee director, Mr. Dobmeier's service on the Board is deemed to have continued uninterrupted. Mr. Dobmeier will continue to serve on the Compensation Committee of the Board.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **JANUX THERAPEUTICS, INC.** | **JANUX THERAPEUTICS, INC.** |
| Date: April 28, 2026 | By: | /s/ David Campbell, Ph.D. |
|  |  | David Campbell, Ph.D. |
|  |  | President and Chief Executive Officer |

---

------